Key facts

Invented name
Tremfya
Active Substance
Guselkumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0399/2022
PIP number
EMEA-001523-PIP04-19-M01
Pharmaceutical form(s)
  • Solution for injection
  • Solution for injection in pre-filled syringe
  • Solution for injection in pre-filled pen
Condition(s) / indication(s)
Treatment of ulcerative colitis
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries

Janssen-Cilag International N.V.

Tel. +32 14602111
E-mail: contact@Janssen-emea.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0399/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for guselkumab (Tremfya), (EMEA-001523-PIP04-19-M01)

How useful do you find this page?